MOH Molina Healthcare Inc

$MOH Is a buy 👀 Price has tagged off the 200DMA and shown a strong reaction. I'm happy starting a position, however I still expect a test of the 0.618 fib. Short term Wave 3 target: 85% 🚀

$MOH Wants lower 👀 Price has rejected the 0.5 fib for the 2nd time and has lost the trendline. I expect a move towards the 200DMA next where I'll likely start a position. Wave 3 target: 117% 🚀

$MOH am liking this lil thang, dancing on the trendy on the hourly .. show me where you want to go, make up your mind and I shall join with my peasant bag ❤️

$MOH Up 4% yesterday 👀 Price looks to retest the 0.5 fib with a possible extension to the 0.618 fib. No change to the downside target and I'll continue to stay patient. Wave 3 target: 117% 🚀

$MOH Soon: medical cost ratio going down. The tenure curve, from the Counterpart whitepaper published December 2025, data as of September 30 2025: Year 1: 8 percent Year 2: 12 percent Year 3: 18 percent Year 4: 20 percent Clover Assistant is software that sits in front of the primary care doctor during the visit. It pulls claims, specialist charts, EHR data, pharmacy and lab results into one view of the member, then surfaces suspected diagnoses and open care gaps while the doctor is still in the room. Clover pays an enhanced rate for visits documented in it, which is why doctors actually use it. That enhanced rate is stated in the 10K. The mechanism is not complicated. Find the condition early, treat it early, and it does not turn into an admission two years later. Year one looks modest because that is the year you are finding things. By year three and four the cohort is managed and the curve bends.